Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Abstract

The infection of a novel coronavirus found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for 2019-nCoV, various strategies are being tested in China, including drug repurposing. In this study, we used our pretrained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of 2019-nCoV. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing a inhibitory potency with K d of 94.94 nM against the 2019-nCoV 3C-like proteinase, followed by efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of 2019-nCoV with an inhibitory potency with K d < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra, could be used for the treatment of 2019-nCoV, although there is no real-world evidence supporting the prediction. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for 2019-nCoV.

Cited by papers we hold 10

• Opinion analysis and aspect understanding during covid-19 pandemic using BERT-Bi-LSTM ensemble method · 2022
  Not checked
• Deep learning in drug discovery: an integrative review and future challenges · 2022
  No notice
• AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate · 2021
  Not checked
• De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning · 2021
  Not checked
• Artificial intelligence vs COVID-19: limitations, constraints and pitfalls · 2020
  No notice
• COVID-19: Understanding the Pandemic Emergence, Impact and Infection Prevalence Worldwide · 2020
  Not checked
• Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines · 2020
  Not checked
• Artificial Intelligence (AI) and Big Data for Coronavirus (COVID-19) Pandemic: A Survey on the State-of-the-Arts · 2020
  No notice
• COVID-19 Patient Health Prediction Using Boosted Random Forest Algorithm · 2020
  No notice
• Essential Oils as Antiviral Agents, Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.